Capricor Advances Duchenne Treatment with FDA Submission

Capricor Therapeutics ( (CAPR) ) has issued an update.

Capricor Therapeutics has begun the rolling submission process for a Biologics License Application with the FDA, aiming for the approval of deramiocel, a promising new treatment for Duchenne muscular dystrophy cardiomyopathy. Set to complete the submission by the end of 2024, the company is hopeful for deramiocel’s potential as it could significantly improve the treatment landscape for this serious condition, with a possibility of expedited review by the FDA.

See more insights into CAPR stock on TipRanks’ Stock Analysis page.